Moderna walks away from potential $3B gene editing deal with Metagenomi
Citing a strategic prioritization by Moderna, Metagenomi announced that the partners have “mutually agreed” to terminate their gene editing agreement.
If you are not happy with the results below please do another search
Citing a strategic prioritization by Moderna, Metagenomi announced that the partners have “mutually agreed” to terminate their gene editing agreement.
The collaboration is designed to combine “the innovative cell therapy platforms from each of the companies,” according to the announcement.
Healthcare and drug industry groups on Wednesday urged a U.S. appeals court to revive their challenge to a law requiring manufacturers to negotiate the prices of some drugs with the U.S government’s Medicare health insurance program or pay heavy penalties.
Dedicated to the growth and development of Peregrine, Schmid has been elevated to partner, and Deng was promoted to senior content strategist, with the responsibility of leading projects in collaboration with an interdepartmental team of strategists, copywriters, art directors, and account service representatives to help clients identify opportunities for managed market–focused content development.
In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different pharmaceutical products, disputing the accuracy and relevance of their patents.
Neurocrine Biosciences won the FDA’s approval for a sprinkle capsule formulation of Ingrezza, providing a more convenient route of treatment for Huntington’s disease patients with trouble swallowing.
Denmark will start putting patients suffering from type 2 diabetes on cheaper drugs before prescribing so-called GLP-1 drugs such as Novo Nordisk’s Ozempic, the Danish Medicines Agency.
Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday.
Johnson & Johnson is moving forward with a $6.475 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products contain asbestos and cause ovarian cancer, the company said today in a statement.
CEO Emma Walmsley’s strategy has focussed on vaccines, cancer and infectious diseases and a shift in the company’s HIV focus to long-acting treatment and prevention therapies. The strategy has paid off as GSK gears up for 12 launches from 2025.